International incidence and mortality trends of liver cancer: a global profile

Wong, Martin Cs; Jiang, Jianfa; Goggins, William B.; Liang, Miaoyin; Fang, Yuan; Fung, Francis; Leung, Colette; Wang, Haoxiang; Wong, Grace Lai–Hung; Wong, Vincent Wai‐Sun; Chan, Henry Lik‐Yuen

doi:10.1038/srep45846

Cited by 221 publications

(198 citation statements)

References 29 publications

Supporting

Mentioning

186

Contrasting

Unclassified

Order By: Relevance

“…22 In 2012, Eastern Asia was noted to have the highest HCC-related incidence and mortality in both genders in the World. 23 According to Asian-Pacific clinical practice guideline, there was a clear difference of incidence and mortality in this region. 22 For example, the cause of HCC in Japan (mainly HCV) differs greatly from other countries (mainly HBC) in the region.…”

Section: Discussionmentioning

confidence: 99%

Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016

Kim

et al. 2018

Journal of Viral Hepatitis

View full text Add to dashboard Cite

The Asian American population is characterized by remarkable diversity. Studying Asians as an aggregate group may obscure clinically meaningful heterogeneity. We performed a population-based study using data from the US National Vital Statistics System. We determined the trends in age-standardized mortality rates for chronic liver disease stratified by aetiology among the most populous US-based Asian subgroups (Asian Indians, Chinese, Filipino, Japanese, Korean and Vietnamese) and compared it to non-Hispanic whites. Annual percentage change was calculated to determine temporal mortality patterns using joinpoint analysis. Hepatitis C virus-related mortality rates were higher in non-Hispanic whites compared to individual Asian subgroups, but a sharp decline in mortality rates was noted in 2014 among non-Hispanic whites and all Asian subgroups. Age-standardized hepatitis B virus-related mortality rates were higher in all Asian subgroups as compared to non-Hispanic whites in 2016, with the highest mortality among Vietnamese followed by Chinese. Mortality rates for alcoholic liver disease have been steadily trending upwards in all Asian subgroups, with the highest mortality in Japanese. Overall, age-standardized cirrhosis-related mortality rates were highest in non-Hispanic whites, followed by Japanese, and more distantly by Vietnamese and other subgroups. However, hepatocellular carcinoma-related mortality rates were higher in most Asian subgroups led by Vietnamese, Japanese and Koreans compared to non-Hispanic whites. In this population-based study utilizing a nationally representative database, we demonstrated a marked heterogeneity in the mortality rates of aetiology-specific chronic liver disease among Asian subgroups in the United States.

show abstract

Section: Discussionmentioning

confidence: 99%

Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016

Kim

et al. 2018

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…As for breast cancer, wealthier countries tended to have higher incidence rate (14,15), with the ASIR in more developed countries two times as high as in less developed countries (10). In China, positive correlation between breast cancer mortality rate and GDPPC was found (16). Researches based on GLOBOCAN data showed that liver cancer incidence and mortality was negatively correlated with GDPPC (17), and cervical cancer incidence and mortality rates in developing countries were two-fold and three-fold higher respectively than women in developed countries (18).…”

Section: Introductionmentioning

confidence: 92%

“…With regard to China, there are only a handful of articles on the association between economic factors and the pattern of a certain cancer in certain cities (16,22). High-GDPPC areas had both the highest crude incidence and mortality rates, followed by middle-and low-GDPPC areas.…”

Section: Discussionmentioning

confidence: 99%

Comparison of cancer incidence and mortality in three GDP per capita levels in China, 2013

Yang

Zheng

Zhang

et al. 2017

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

Objective: In this research, the patterns of cancer incidence and mortality in areas with different gross domestic product per capita (GDPPC) levels in China were explored, using data from population-based cancer registries in 2013, collected by the National Central Cancer Registry (NCCR).Methods: Data from 255 cancer registries were qualified and included in this analysis. Based on the GDPPC data of 2014, cities/counties were divided into 3 levels: high-, middle-and low-GDPPC areas, with 40,000 and 80,000 RMB per year as cut points. We calculated cancer incidences and mortalities in these three levels, stratified by gender and age group. The national population of the Fifth Census in 2000 and Segi's population were applied for age-standardized rates. Results:The crude incidence and mortality rates as well as age-standardized incidence rate (ASIR) showed positive associations with GDPPC level. The age-standardized mortality rate (ASMR) nevertheless showed a negative association with GDPPC level. The ASMR in high-, middle-and low-GDPPC areas was 103.12/100,000, 112.49/100,000 and 117.43/100,000, respectively. Lung cancer was by far the most common cancer in all three GDPPC levels. It was also the leading cause of cancer death, regardless of gender and GDPPC level. Negative associations with GDPPC level were found for the ASIRs of lung, stomach, esophageal and liver cancer, whereas colorectal and breast cancer showed positive associations. Except for breast cancer, the ASMRs of the other five cancers were always higher in middle-and low-GDPPC areas than in high-GDPPC areas. Conclusions:The economic development is one of the main factors of the heavy cancer burden on Chinese population. It would be reasonable to implement cancer control strategies referring to the local GDPPC level.

show abstract

“…In the United States, age‐adjusted mortality rates for liver cancer increased by 43% between 2000 and 2016 . Increasing secular trends in incidence and mortality have been observed across many countries including the United Kingdom, Poland, Brazil, Germany and Norway . Major risk factors for liver cancer include hepatitis C virus (HCV) infection, hepatitis B virus (HBV) infection, heavy alcohol drinking and nonalcoholic fatty liver disease (NAFLD) .…”

Section: Introductionmentioning

confidence: 99%

Statin use and risk of liver cancer: Evidence from two population‐based studies

Tran

McMenamin

Coleman

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Epidemiological studies of statin use and liver cancer risk have produced conflicting results. We examined the association between statin use and risk of primary liver cancer in two large independent study populations taking account of important covariates and main indications of statins such as high cholesterol and chronic liver disease. We performed a nested case–control study within the Scottish Primary Care Clinical Informatics Unit (PCCIU) database. Five controls were matched to cases with primary liver cancer and we used conditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for associations with statin use. We also conducted a prospective cohort study within the UK Biobank using self‐reported statin use and cancer‐registry recorded primary liver cancer outcomes. Cox regression was used to calculate hazard ratios (HRs) and 95% CIs. In the PCCIU case–control analysis, 434 liver cancer cases were matched to 2,103 controls. In the UK Biobank cohort, 182 out of 475,768 participants developed incident liver cancer. Statin use was associated with 39% lower risk of liver cancer in the PCCIU (adjusted OR 0.61, 95% CI 0.43–0.87). When we examined specific subtypes of liver cancer in the UK Biobank, statin use was associated with lower risk of hepatocellular carcinoma (HCC; adjusted HR, 0.48; 95% CI, 0.24–0.94) but not intrahepatic bile duct carcinoma (IBDC; adjusted HR, 1.09; 95% CI, 0.45–2.64). In conclusion, we found a consistent inverse relationship between statin use and risk of primary liver cancer which was only seen for HCC but not IBDC.

show abstract

International incidence and mortality trends of liver cancer: a global profile

Cited by 221 publications

References 29 publications

Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016

Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016

Comparison of cancer incidence and mortality in three GDP per capita levels in China, 2013

Statin use and risk of liver cancer: Evidence from two population‐based studies

Contact Info

Product

Resources

About